Affiliation:
1. Department of Breast Surgery, Tokyo Women’s Medical University Medical Center East
Publisher
The Japanese Society of Strategies for Cancer Research and Therapy
Subject
Pharmacology (medical),Cancer Research,Oncology
Reference23 articles.
1. 1) Shirasaka T., Shimamoto Y., Ohshimo H., Yamaguchi M., Kato T., Yonekura K., Fukushima M. (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548-557.
2. 2) Takechi T., Nakano K., Uchida J., Mita A., Toko K., Takeda S., Unemi N., Shirasaka T. (1997) Antitumor activity and low intesti nal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother. Pharmacol. 39: 205- 11.
3. 3) Sasako M., Sakuramoto S., Katai H., Kinoshita T., Furukawa H., Yamaguchi T., Nashimoto A., Fujii M., Nkajima T., Ohashi Y. (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J. Clin. Oncol. 29: 4387-4393.
4. 4) Fukutomi A., Uesaka K., Boku N., Kanemoto H., Konishi M., Matsumoto I. (2013) JASPAC-01: Randomized phase III trial of ad juvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer. J. Clin. Oncol. 31: suppl, abstr. 4008.
5. 5) Mizushima T., Ide Y., Murata K., Ohashi I., Yasumasa K., Fukunaga M., Takemoto H., Tamagawa H., Hasegawa J., Hata T., Takemasa I., Ikeda M., Yamamoto H., Sekimoto M., Nezu R., Doki Y., Mori M. (2013) A phase II study of combined chemotherapy with 5-week cycles of S-1 and CPT-11 plus bevacizumab in patients with metastatic colon cancer. Oncology 85: 317-22.